tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position
PremiumRatingsPositive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position
2M ago
Positive Outlook for Maze Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating
Premium
Ratings
Positive Outlook for Maze Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating
4M ago
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year
Premium
The Fly
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year
4M ago
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829
PremiumRatingsMaze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829
5M ago
Maze Therapeutics initiated with an Overweight at JPMorgan
Premium
The Fly
Maze Therapeutics initiated with an Overweight at JPMorgan
5M ago
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market
Premium
Ratings
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100